Arlington, MA, United States of America

Constance Martin

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 16.0

ph-index = 1


Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Constance Martin from Arlington, MA

Introduction: Constance Martin is a prominent inventor based in Arlington, Massachusetts, recognized for her significant contributions to the field of biopharmaceuticals. With two patents to her name, she has demonstrated a remarkable ability to innovate within the arena of therapeutic agents.

Latest Patents: Constance's latest patents include "Isoform-selective TGFB1 inhibitors and use thereof," and "Isoform-selective TGFβ1 inhibitors and use thereof." These patents disclose monoclonal antibodies and antigen-binding fragments capable of selectively inhibiting TGFβ1 and TGFβ2, respectively, with high potency. Both inventions include related compositions, methods, and therapeutic uses that have the potential to advance treatment options for various diseases.

Career Highlights: Constance Martin works at Scholar Rock, Inc., an innovative company focused on developing transformative medicines for patients with serious diseases. Her work involves groundbreaking research that leverages her expertise in the field to create powerful biotherapeutics.

Collaborations: Throughout her career, Constance has collaborated with talented individuals including Abhishek Datta and Allan Capili, contributing to a dynamic team environment that fosters innovation and creative problem-solving.

Conclusion: Constance Martin's work exemplifies the spirit of invention and innovation in the biotechnology sector. Her patents not only highlight her personal achievements but also contribute to the broader landscape of medical advancements, showcasing the importance of continued research and development in improving public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…